Falck K., Grohn P., Sorsa M., et al: Mutagenicity in urine of nurses handling cytostatic drugs. Lancet1:1250-1251,1979
2.
Anderson RW, Puckett WH, Dana WJ, et al: Risk of handling injectable antineoplastic agents. Am J Hosp Pharm39:1881-1887,1982
3.
Bos RP, Leenaars AO, Theuws Jlg, et al: Mutagenicity of urine from nurses handling cytostatic drugs, influence of smoking. Int Arch Occup Environ Health50:356-369, 1982
4.
Kolmodin-Hedman B., Hartvig P., Sorsa M., et al: Occupational handling of cytostatic drugs. Arch Toxicol54:25-33,1983
5.
Nguyen TV, Theiss JC, Matney TS: Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res42:4792-4796, 1982
6.
Staiano N., Gallelli JF, Adamson RH, et al: Lack of mutagenic activity in urine from hospital pharmacists admixing antitumor drugs. Lancet1:615-616, 1981
7.
Crudi CB: A compounding dilemma: I've kept the drug sterile but have I contaminated myself. Natl IV Therapy Assoc3:77-78, 1980
8.
Hemminki K., Kygronen P., Lindbohm ML: Spontaneous abortions and malformations in the offspring of nurses exposed to anesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health39:141-147,1985
9.
Knowles RS, Virden TE: Handling of injectable antineoplastic agents. Br Med J281:589-591,1980
10.
Selevan SG, Lindbohm MJ, Hornung RW, et al: A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med313:1173-1178, 1985
11.
Sotaniemi EA , Sutinen S., Arranto AJ, et al: Liver damage in nurses handling cytostatic agents. Acta Med Scand214:181-189, 1983
12.
American Society of Hospital Pharmacists: Disposal of unused anticancer drugs. The Signal, May 1979
13.
American Society of Hospital Pharmacists : ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm47:1033-1049, 1990
14.
Clinical Oncological Society of Australia : Guidelines and recommendations for safe handling of antineoplastic agents. Med J Aust1:426-428, 1983
15.
AMA Council Report: Guidelines for handling parenteral antineoplastics. JAMA March 15, 1985
16.
Harrison BR : Developing guidelines for working with antineoplastic drugs. Am J Hosp Pharm38:1686-1693,1981
17.
Hoffman DM: The handling of antineoplastic drugs in a major cancer center. Hosp Pharm15:302-304,1980
18.
Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs, NIH Publication No. 83-2621. Superintendent of Documents, US Government Printing Office, Washington, DC.
19.
Knowles RS, Virden JE: Handling of injectable antineoplastic agents. Br Med J281:589-591, 1980
20.
Occupational Safety and Health Administration (OSHA): Work practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Am J Hosp Pharm43:1193-1204,1986
21.
Stolar MH, Power LA, Viele CS: Recommendations for handling cytotoxic drugs in hospitals. Am J Hosp Pharm40:1163-1171,1983
22.
Tortorici MP : Precautions followed by personnel involved with the preparation of parenteral antineoplastic medications. Hosp Pharm15:293-301, 1980
23.
Zimmerman PF , Larsen RK, Barkley EW, et al: Recommendations for the safe handling of injectable antineoplastic drug products. Am J Hosp Pharm38:1693-1695, 1981
24.
National Study Commission on Cytotoxic Exposure: Recommendations for Handling Cytotoxic agents, 1987 (available from Louis P. Jeffrey, ScD, Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Ave, Boston, MA 02115)
25.
Harris CC: The carcinogenicity of anticancer drugs: A hazard in man. Cancer37:1014-1023, 1976
26.
Sieber SM, Adamson RH: Toxicity of antineoplastic agents in man: Chromosomal aberrations, antifertility effects, congenital malformations and carcinogenic potential . Adv Cancer Res22:57-69,1975
27.
Nicholson HO : Cytotoxic drugs in pregnancy: Review reported cases. J Obstet Gynaecol Br Common75:307-312, 1968
28.
Reimer RR, Hover R., Fraumeni JF, et al: Acute leukemia after alkylating agent therapy of ovarian cancer . N Engl J Med297:177-81, 1977
29.
Rosner F.: Acute leukemia as a delayed consequence of cancer chemotherapy. Cancer37:1033-1036,1976
30.
Barole A.: Sister-chromatid exchanges in lymphocytes and mutagenicity in urine of nurses handling cytostatic drugs. Mutat Res157:235-240, 1985
31.
Cloak MM, Connor TH, Stevens KR, et al: Occupational exposure of nursing personnel to antineoplastic agents. OccupNurs Forum12:33-39, 1985
32.
Gibson JF, Gompertz D., Hedworth-Whitty RB: Mutagenicity of urine from nurses handling cytostatic drugs. Lancet1:100-101, 1984
33.
Newman MA: Biological monitoring for antineoplastic drugs. Doctoral thesis, University of Cincinnati College of Medicine, Cincinnati, OH, 1986
34.
Ratcliffe JM: Occupational exposure to cancerchemotherapeutic agents in pharmacists and nurses, summary report of NIOSH industrywide studies EP:80:41. National
35.
Institute of Occupational Safety and Health, United States Public Health Service, 1983
36.
Rorth M., Jorgenson V., Knudsen I., et al: (Mutagenicitet i urine hos sygeplejersker pa onkologisk afdeling). Danish, Ugeskrift for Laeger145:475-478, 1983
37.
Stucker I., Hirsch A., Dolay T., et al: Urine mutagenicity, chromosomal abnormalities and sister chromatid exchanges in lymphocytes of nurses handling cytostatic drugs. Int Arch Occup Environ Health57:195-205,1986
38.
Vernett S., Crofton-Sleigh C., Hunt J., et al: Monitoring of exposure of nursing and pharmacy personnel to cytostatic drugs: Urinary mutation assays and urinary platinum as markers of absorption. Lancet1:74-77, 1984
39.
Nikula E., Kivinitly K., Leistic T., et al: Chromosome abberations in lymphocytes of nurses handling cytostatic agents. Scan J Work EnvironHealth10:71-74, 1984
40.
Norppa H., Sorsa M., Vainio H., Grohn P., Heinonen E., Holsti L., and Norman E.: Increased sister chromatid exchange in frequencies in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health6:299-301, 1980
41.
Stiller A., Obe G., Boll I., et al: No elevation of the frequencies of chromosomal alternations as a consequence of handling cytostatic drugs. Analysis with peripheral blood and urine of hospital personnel. Mutat Res121:253-259, 1983
42.
Waksvik H., Brogger A., Klepp O.: Chromosome analysis of nurses handling sytostatic drugs. Cancer Treat Rep65:607-610,1981
43.
Jagun O., Ryan M., Wadron HA: Urinary thioether excretion in nurses handling cytotoxic drugs. Lancet2:443-444, 1982 (letter)
44.
Hirst M., Mills DG, Tse S., et al: Occupational exposure to cyclophosphamide. Lancet1:186-188, 1984
45.
Celio LA, DiGregorio GJ, Ruch E., et al: Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. Eur J Clin Pharmacol24:261-266, 1983
46.
Chabner BA: Letter to the editor. N Engl J Med314:1049, 1986
47.
Mulvihill JJ , Stewart KR: Letter to the editor. N Engl J Med314:1049,1986
48.
Vaccari PL, Tonat K., DeChristoforo R., et al: Disposal of antineoplastic wastes at the National Institutes of Health. Am J Hosp Pharm41:87-93, 1984
